---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015519"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:48:52.592267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Capricor reports Q3 net loss $12.6M; starts BLA for deramiocel, signs $715M European deal

## Summary
- Q3 net loss $12.6M ($0.38/sh) vs $6.4M ($0.25/sh); revenue $2.3M vs $6.2M.
- Began rolling BLA submission for deramiocel (DMD cardiomyopathy) Oct 2024; full submission expected year-end; PDUFA H2 2025.
- Signed binding term sheet with Nippon Shinyaku for Europe: $20M upfront, up to $715M milestones plus double-digit revenue share.
- Public offering net proceeds ~$80.8M; cash $85M at Sep 30; runway into 2027.
- Nippon Shinyaku purchased ~$15M of CAPR stock at 20% premium.

## SEC filing metadata
- accession: 0001558370-24-015519
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/0001558370-24-015519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015519
- JSON: https://secwatch.observer/filing/0001558370-24-015519.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015519.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.